Cas 1360871-31-3,3-(4-bromophenyl)-7,8-dimethyl-4-(3,4,5-trimethoxyphenyl)imidazo[1,5-a]quinoxaline

1360871-31-3

Post Buying Request

Basic information

Product Name: 3-(4-bromophenyl)-7,8-dimethyl-4-(3,4,5-trimethoxyphenyl)imidazo[1,5-a]quinoxaline
Synonyms:
CAS NO:1360871-31-3
Molecular Formula:
Molecular Weight: 518.41
EINECS: N/A
Product Categories: N/A

Chemical Properties

Melting Point: N/A
Boiling Point: N/A
Flash Point: N/A
Appearance: N/A
Density: N/A
Refractive Index: N/A
Storage Temp.: N/A
Solubility: N/A
CAS DataBase Reference: 3-(4-bromophenyl)-7,8-dimethyl-4-(3,4,5-trimethoxyphenyl)imidazo[1,5-a]quinoxaline(CAS DataBase Reference)
NIST Chemistry Reference: 3-(4-bromophenyl)-7,8-dimethyl-4-(3,4,5-trimethoxyphenyl)imidazo[1,5-a]quinoxaline(1360871-31-3)
EPA Substance Registry System: 3-(4-bromophenyl)-7,8-dimethyl-4-(3,4,5-trimethoxyphenyl)imidazo[1,5-a]quinoxaline(1360871-31-3)

Safety Data

Hazard Codes: N/A
Statements: N/A
Safety Statements: N/A
WGK Germany:
RTECS:
HazardClass: N/A
PackingGroup: N/A
Hazardous Substances Data: 1360871-31-3(Hazardous Substances Data)

Suppliers
Usage
Upstream product
Downstream Products
Article

1360871-31-3 Suppliers

Recommended suppliers

1360871-31-3 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1360871-31-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,6,0,8,7 and 1 respectively; the second part has 2 digits, 3 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 1360871-31:
(9*1)+(8*3)+(7*6)+(6*0)+(5*8)+(4*7)+(3*1)+(2*3)+(1*1)=153
153 % 10 = 3
So 1360871-31-3 is a valid CAS Registry Number.

1360871-31-3Upstream product

150114-69-5 2-oxo-2-(3,4,5-trimethoxyphenyl)acetaldehyde

1360871-31-3Downstream Products

1360871-31-3Relevant academic research and scientific papers

Straightforward assembly of phenylimidazoquinoxalines via a one-pot two-step MCR process

De Moliner, Fabio,Hulme, Christopher

, p. 1354 - 1357 (2012)

An efficient multicomponent-based methodology providing a new entry into a medicinally important complex heterocyclic core is presented. The strategy is very general and able to endow target compounds with the highest possible number of diversity points.

Post a RFQ

Cas No.:

Product Name:

Quantity:

Email:

Company name:

Valid Period:

Detailed Requirements:

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

What can I do for you?
Get Best Price

Get Best Price for 1360871-31-3